More information about the highly anticipated new cholesterol lowering drugs from Amgen and Sanofi/Regeneron emerged today. A new new analysis of available data from early trials with PCSK9 inhibitors adds to the growing evidence showing that the drugs-- Amgen’s evolocumab and Sanofi’s alirocumab-- dramatically lower LDL cholesterol and offers additional preliminary evidence showing that they are [...]